Is Zenith Drugs Ltd (ZENITHDRUG) a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Zenith Drugs Ltd is a below average quality company .

Is Zenith Drugs Ltd (ZENITHDRUG) undervalued or overvalued?

The key valuation ratios of Zenith Drugs Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone .

What is Zenith Drugs Ltd (ZENITHDRUG) share price return in the past 10 years?

Data is not available for this company

Is Zenith Drugs Ltd (ZENITHDRUG) a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Zenith Drugs Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

What is the share price of Zenith Drugs Ltd (ZENITHDRUG)?

Company share prices are keep on changing according to the market conditions. The current trading price of Zenith Drugs Ltd (ZENITHDRUG) on 01-Jan-1970 05:30:00 at 05:30 is .

What is the P/E ratio of Zenith Drugs?

The latest standalone P/E ratio of Zenith Drugs as of 01-Jan-1970 is 10.57.

What is the P/B ratio of Zenith Drugs Ltd (ZENITHDRUG)?

The latest standalone P/B ratio of Zenith Drugs Ltd (ZENITHDRUG) as of 01-Jan-1970 is 1.09.

What is the 52-week high and low of Zenith Drugs Ltd (ZENITHDRUG)?

The 52-week high of Zenith Drugs Ltd (ZENITHDRUG) is Rs. 0.00 and the 52-week low is Rs. 0.00.

Zenith Drugs Ltd (ZENITHDRUG) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Zenith Drugs Ltd (ZENITHDRUG)
Brand: Zenith Drugs

Zenith Drugs Ltd (ZENITHDRUG) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Zenith Drugs Ltd (ZENITHDRUG)

BSE: 0 NSE: ZENITHDRUG

Key Metrics

Market Cap

₹76 Cr.

P/E Ratio

10.57

Price to Book (P/B)

1.09

Price to Sales (P/S)

0.57

EV/EBITDA

7.55

Return on Capital Employed (ROCE)

12.96%

Current Price

₹0

Return on Equity (ROE)

10.88%

Return on Assets (ROA)

4.85%

Operating Profit Margin

10.4%

Net Profit Margin

5.37%

Gross Profit Margin

8.2%

Book Value per Share

₹40.5

Sales Growth (YoY)

1.29%

Sales Growth (3 Years)

13.3%

Operating Profit Growth (1 Year)

-16.69%

Operating Profit Growth (3 Years)

25.96%

Net Profit Growth (1 Year)

-24.95%

52-Week Low / High

₹0 / 0

Net Profit Growth (3 Years)

30.62%

Dividend Yield

0.00%

Promoter Holding

69.98%

Pledged shares (%)
of Promoter's holding (%)

0.00%

Check Before You Invest

Q.1 Revenue growth of Zenith Drugs Ltd?

Zenith Drugs Ltd revenue growth is 1.3% for FY-2025 , which is above its 5 year CAGR of 0% , indicating faster growth.

Q.1 Promoter shareholding and pledge status of Zenith Drugs Ltd?

Promoters hold 69.98% of the Zenith Drugs Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Revenue growth of Zenith Drugs Ltd vs industry peers?

Zenith Drugs Ltd revenue CAGR is 0.00% , compared to the industry median CAGR of 5.54% , indicating slower growth and losing its market share.

Q.1 Which industry/sub-sector does Zenith Drugs Ltd belong to?

Zenith Drugs Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.

Q.1 Stock return of Zenith Drugs Ltd over the last decade?

Over the last 1 year(s), the stock has delivered a CAGR of -49.83% based on the current price.

DeciZen - make an informed investing decision on Zenith Drugs

Based on:

Data

M-Cap below 100cr DeciZen not available

Zenith Drugs stock performance

Key Ratios

Is Zenith Drugs Ltd an attractive stock to invest in?

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	24.3%	23.9%	25.1%	25.2%	13%	-
Value Creation Index ⓘ	0.7	0.7	0.8	0.8	-0.1	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	73.4	91.7	115	132	133	133
Sales YoY Gr.	-	24.9%	24.9%	14.9%	1.3%	-
Adj EPS ⓘ	2.6	2.7	4.5	6.2	4.3	4.2
YoY Gr.	-	4.7%	69%	36.9%	-31.3%	-
BVPS (₹) ⓘ	8	10.7	14.8	36.3	40.5	40.5
Adj Net Profit ⓘ	3.1	3.2	5.4	10.6	7.3	7
Cash Flow from Ops. ⓘ	-0.9	4.9	-4.3	-15.8	-5.5	-
Debt/CF from Ops. ⓘ	-17.5	3.4	-6	-1.5	-8.9	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	NA	NA	13.3%	1.3%
Adj EPS ⓘ	NA	NA	16.7%	-31.3%
BVPSⓘ	NA	NA	55.7%	11.5%
Share Price	-	-	-	-50.7%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	31.8	28.6	35.5	26.6	11.1	10.3
Op. Profit Mgn % ⓘ	9.8	7.6	8.8	12.6	10.4	NAN
Net Profit Mgn % ⓘ	4.2	3.5	4.8	8.1	5.5	5.4
Debt to Equity ⓘ	1.6	1.3	1.4	0.4	0.7	-
Working Cap Days ⓘ	0	159	198	239	274	0
Cash Conv. Cycle ⓘ	0	16	14	37	103	0

Recent Performance Summary

Latest Financials

	Standalone	Consolidated
TTM EPS (₹)	4.2	5.6
TTM Sales (₹ Cr.)	133	132
BVPS (₹) ⓘ	40.5	36.3
Reserves (₹ Cr.) ⓘ	52	45
P/BV ⓘ	1.09	1.22
PE ⓘ	10.57	7.89

From the Market
52 Week Low / High (₹)	0.00 / 0.00
All Time Low / High (₹)	- / -
Market Cap (₹ Cr.)	75.7
Equity (₹ Cr.)	17.2
Face Value (₹)	10
Industry PE ⓘ	42.1

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Zenith Drugs - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Key Ratios

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	73.40	91.66	114.52	131.62	133.32
Operating Expenses ⓘ +	66.20	84.73	105.31	115.02	119.49
Manufacturing Costs	1.54	2.73	29.34	37.13	34.55
Material Costs	52.41	72.51	56.42	56.70	63.46
Employee Cost	2.41	2.98	4.09	5.34	6.76
Other Costs ⓘ	9.84	6.51	15.46	15.84	14.72
Operating Profit ⓘ	7.20	6.92	9.21	16.60	13.83
Operating Profit Margin (%)	9.8%	7.6%	8.0%	12.6%	10.4%
Other Income ⓘ +	0.11	0.95	1.24	2.55	2.61
Exceptional Items ⓘ	0	0	0	-1.56	-0.25
Interest ⓘ	1.49	2.14	2.49	3	3.96
Depreciation ⓘ	1.22	1.34	1.30	1.30	2.97
Profit Before Tax ⓘ	4.60	4.40	6.66	13.29	9.26
Tax ⓘ	1.53	1.19	1.78	3.76	2.10
Profit After Tax	3.07	3.21	4.88	9.54	7.16
PAT Margin (%)	4.2%	3.5%	4.3%	7.3%	5.4%
Adjusted EPS (₹)	2.6	2.7	4.1	5.6	4.2
Dividend Payout Ratio (%)	0%	0%	0%	9%	0%

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	9.64	12.85	17.73	62.22	69.38
Share Capital ⓘ	0.40	0.40	0.40	17.15	17.15
Reserves ⓘ	9.24	12.45	17.33	45.07	52.23
Debt +	15.48	16.79	23.46	21.86	42.99
Long Term Debt	7.28	7.58	7.67	7.85	12.80
Short Term Debt	8.21	9.20	15.79	14.01	30.19
Minority Interest	0	0	0	0	0
Trade Payables	20.26	34.40	50.87	42.63	40.18
Others Liabilities ⓘ	1.16	2.15	5.16	7.40	8.92
Total Liabilities ⓘ	46.54	66.18	97.22	134.11	161.47
Fixed Assets
Net Fixed Assets ⓘ +	9.21	10.45	10.82	10.94	40.26
Gross Block	14.23	16.80	18.48	19.90	52.18
Accumulated Depreciation	5.01	6.35	7.66	8.96	11.92
CWIP ⓘ	0	0	0	3.91	3.10
Investments ⓘ	0	0.03	0.03	0.03	0
Inventories	6.83	12.13	23.67	25.76	39.61
Trade Receivables	23.39	32.07	49.31	67.39	60.58
Cash Equivalents	1.85	2.89	0.20	8.74	0.26
Others Assets ⓘ	5.26	8.62	13.19	17.34	17.65
Total Assets ⓘ	46.54	66.18	97.22	134.11	161.47

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	-0.89	4.91	-4.27	-15.84	-5.47
PBT ⓘ	4.60	4.40	6.66	13.29	9.51
Adjustment ⓘ	2.53	3.47	3.63	4.30	6.38
Changes in Working Capital ⓘ	-6.67	-1.72	-12.73	-26.44	-15.6
Tax Paid ⓘ	-1.36	-1.24	-1.83	-3.99	-2.05
Cash Flow From Investing Activity ⓘ +	-1.43	-2.61	-2.05	-5.33	-31.41
Capex	-1.43	-2.61	-1.67	-1.42	-32.28
Net Investments	0	0	0	0	0.07
Others ⓘ	0	0	-0.38	-3.91	0.81
Cash Flow From Financing Activity ⓘ +	2.88	-0.83	6.30	29.72	28.39
Net Proceeds from Shares ⓘ	0	0	0	34.95	0
Net Proceeds from Borrowing ⓘ	0	0	0.09	0.18	4.94
Interest Paid ⓘ	-1.32	-2.14	-2.33	0	0
Dividend Paid ⓘ	0	0	0	0	0
Others ⓘ	4.20	1.30	8.54	-5.42	23.45
Net Cash Flow ⓘ	0.57	1.47	-0.01	8.55	-8.48

Finance Ratio

PARTICULARS	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	31.82	28.57	31.92	23.86	10.88
ROCE (%)	24.25	23.87	25.12	25.2	12.96
Asset Turnover Ratio	1.74	1.8	1.57	1.3	1.03
PAT to CFO Conversion(x)	-0.29	1.53	-0.88	-1.66	-0.76
Working Capital Days
Receivable Days	105	100	116	142	154
Inventory Days	31	34	51	60	79
Payable Days	141	138	276	301	238

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Zenith Drugs Ltd FAQs

The current trading price of Zenith Drugs on 01-Jan-1970 05:30 is ₹0.00.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Zenith Drugs stood at ₹75.71 Cr

The latest P/E ratio of Zenith Drugs as of 31-Dec-1969 is 10.57.

The latest P/B ratio of Zenith Drugs as of 31-Dec-1969 is 1.09.

The 52-week high of Zenith Drugs is ₹0.00 and the 52-week low is ₹0.00.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Zenith Drugs is ₹133 ( Cr.) .

About Zenith Drugs Ltd

Zenith Drugs Limited was originally incorporated on November 15, 2000 as a Private Limited Company in the name of ‘Zenith Drugs Private Limited’ under the provisions of the Companies Act, 1956 with the Registrar of Companies, Madhya Pradesh, Gwalior. Subsequently pursuant to a Special Resolution of its Shareholders passed in the Extra-Ordinary General Meeting held on September 05, 2023, the Company was converted from a Private Limited Company to Public Limited Company and consequently, the name of the Company was changed to ‘Zenith Drugs Limited’ and a Fresh Certificate of Incorporation consequent to Conversion was issued on September 13, 2023 by the Registrar of Companies, Gwalior.

The company is a pharmaceutical manufacturing and trading company based out from Indore. It has a manufacturing unit, dedicated to ensuring the highest quality standards when it comes to manufacturing of medicines. It is specialized in manufacturing high quality and affordable Medicines to support its patients in need. The company is also into Generic Medicines and Generic Medicines are cost effective. Since its inception, the company has focused on building a strong foundation and laying the groundwork for its future growth and success. With dedication and strategic planning, it managed to establish a reputable presence in the pharmaceutical industry. The company was incorporated with the objective of the better service deliverance in field of medicine and be better premium pharmaceutical companies in India and abroad for cost effective human medicine. The company always emphasis on core strength and policies that focus on technology and great deliverance. With a passion to set high standards of services, the company has always taken all measures to scale up as and when required only to deliver the better. The company works diligently and has a wide range of products to cater to every need and to reach the client sensitivity and centricity.

The company has Certificate of Good Manufacturing Practices issued by Office of the Controller, Food and Drugs Administration, Madhya Pradesh, Idgah Hills, Bhopal, Madhya Pradesh. The quality standards of the company are based on adherence to Good Manufacturing Practices (GMP) guidelines, regulatory requirements and internal quality control processes. The Company is constantly required to adhere to the same. These measures are implemented to ensure the highest level of quality in its manufacturing operations. Building upon its commitment to excellence, it has completed two expansions within the same facility to accommodate the growing demand for its products. These expansions have allowed the company to scale its operations, increase production capacity, and introduce new formulations. Through these strategic investments and expansions, the company strives to continuously improve its manufacturing infrastructure, enhance product quality, and meet the evolving needs of healthcare professionals and patients.

Business area of the company

The company is mainly engaged in the business of manufacturing and Trading of Medicines.

Products of the company

Liquid oral

Iron & Folic acid syrup IP
Hungrykop syrup
BIozen multivitamin syrup
Rexkop DX syrup
Zoomol plus syrup

Ointment / Cream

POVIZ ointment
Clobetol GM cream
Painfree gel
Poviz M ointment
Candizen cream

Liquid external section

Poviz solutin (Lotion)
Bioscaby lotion
Permethirn lotion
Gamma Benzene Hexachloride 1% lotion
Scabikop lotion

Capsule section

Pyvoxee spas plus capsule
BIO-Omi capsule
Lopagen capsule
Cold-time capsule
Rabijen DSR capsule

ORS section

Zenith ORS
Koplyte ORS
Oral rehydration salts IP 20.50 gm
Oral rehydration salts BP 27.90 gm

History and milestones

2000: Incorporation of the Company.
2001: Started as a manufacturing house for oral and external formulations.
2004: Shifted to a Schedule M GMP compliant unit.
2004: Started the production of two lines which are liquid orals and ointments.
2007: Started manufacturing ORS Powder.
2016: Received WHO GMP certification.
2019: Turnover crossed Rs 50 crore.
2020: Turnover crossed Rs 75 crore.
2021: Certificate of Quality Management System ISO 9001:2015 issued by Global Grading Certification.
2021: Certificate of compliance with good manufacturing practices issued by Liberia Medicines and Health Products Regulatory Authority.
2021: The Company received subsidy under Madhya Pradesh MSME Yojna i.e. MSME Promotion Scheme, 2019 as Industrial Development Grant upto 40% of the capital invested in machinery i.e. grant of Rs 170.04 lakh.
2022: The Company was recognized as among top 10 MSME Pharmaceutical Manufacturers in Indore in Industry Outlook Magazine Edition.
2023: Turnover crossed Rs 100 crore.
2023: Collaborated with Mr. Kshatriya Valtaprasad Nandkishore for Carrying out the task of Marketing and Export of the products manufactured by Zenith.
2023: Conversion of the Company from Private Limited Company to Public Limited Company.

To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

Build a Stress-Tested Portfolio.

Our Sapphire Advisory uses the ABC Concept to ensure you never have to panic during a market correction.

Core Stocks

STABILITY

Booster Stocks

GROWTH

Amplifier Stocks

ASYMMETRY

● Conflict-Free ● SEBI Registered ● 15Y+ Track Record

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Zenith Drugs Ltd (ZENITHDRUG) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating